{"id":"NCT01550965","sponsor":"AbbVie (prior sponsor, Abbott)","briefTitle":"A Study to Evaluate the Impact of Adalimumab on Quality of Life, Health Care Utilization and Costs of Ulcerative Colitis Subjects in the Usual Clinical Practice Setting","officialTitle":"An Open-Label Multicenter Study to Evaluate the Impact of Adalimumab on Quality of Life, Health Care Utilization and Costs of Ulcerative Colitis Subjects in the Usual Clinical Practice Setting","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-05","primaryCompletion":"2015-04","completion":"2015-04","firstPosted":"2012-03-12","resultsPosted":"2016-11-01","lastUpdate":"2018-07-02"},"enrollment":463,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Ulcerative Colitis"],"interventions":[{"type":"BIOLOGICAL","name":"Adalimumab","otherNames":["ABT-D2E7","HumiraÂ®"]}],"arms":[{"label":"Participants Receiving Adalimumab","type":"EXPERIMENTAL"}],"summary":"This study evaluated the quality of life (QOL) and economic impact of adalimumab treatment in participants with ulcerative colitis (UC).","primaryOutcome":{"measure":"Mean Change From Baseline in Short Inflammatory Bowel Disease Questionnaire (SIBDQ): Total Score","timeFrame":"Week 0 (baseline) and Week 26","effectByArm":[{"arm":"Participants Receiving Adalimumab","deltaMin":17.4,"sd":14.48}],"pValues":[{"comp":"OG000","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["28981846"],"seeAlso":["http://www.rxabbvie.com"]},"adverseEventsSummary":{"seriousAny":{"events":67,"n":463},"commonTop":["COLITIS ULCERATIVE","HEADACHE","NASOPHARYNGITIS","ARTHRALGIA","NAUSEA"]}}